G6PD and small cell lung carcinoma: RRx-001 is an effective inhibitor of G6PD and has been used in several clinical trials for SCLC, including a phase II clinical trial in which sensitization was performed in SCLC patients with acquired resistance to first-line chemotherapy with the etoposide plus cisplatin (EP) regimen [27,28].